Neuromuscular

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Sharon Hesterlee, PhD, president and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

Here's some of what is coming soon to NeurologyLive® this week.

At NSGC 2025, the research director at the Clinic for Special Children discussed the clinic’s approach to accelerating the diagnosis and treatment of spinal muscular atrophy. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending November 29, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

The director of the Les Turner ALS Center at Northwestern Medicine talked about his lab’s preclinical research on identifying genetic targets for neurodegenerative diseases. [WATCH TIME: 5 minutes]

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending November 22, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

The senior director of research and real world data at Genome Medical talked about the benefits and challenges of genetic counselors adopting artificial intelligence tools. [WATCH TIME: 5 minutes]

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

The genetic counselor in the Department of Ophthalmology at the University of Pittsburgh Medical Center talked about the evolving role of genetic counselors in guiding patients through gene therapy. [WATCH TIME: 4 minutes]

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.